Specification of fictitious added benefit upon market access of orphan drugs not confirmed

By | January 13, 2022
In order to promote the development of drugs for rare diseases (orphan drugs) despite market risks, in Germany they are exempt from the regular benefit assessment procedure introduced in 2011 with the Act on the Reform of the Market for Medicinal Products (AMNOG).